Extracellular protease imaging for cell mass tracking of xenografted human malignant pleural mesothelioma

Zhou,Lanlan; El-Deiry,Wafik; Wang,Wenge; Ingram,Mary  E.; Katz,Sharyn  I.

doi:10.3892/or.2012.1888

Extracellular protease imaging for cell mass tracking of xenografted human malignant pleural mesothelioma

Authors:
- Lanlan Zhou
- Wafik El-Deiry
- Wenge Wang
- Mary E. Ingram
- Sharyn I. Katz
View Affiliations

Affiliations: Department of Medicine (Hematology/Oncology), Laboratory of Translational Oncology and Experimental Cancer Therapeutics, Penn State College of Medicine, Penn State Hershey Cancer Institute, Penn State Hershey Medical Center, Hershey, PA, USA, Department of Internal Medicine, Mount Vernon Hospital, Mount Vernon, NY, USA, Department of Radiology, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA
Published online on: June 26, 2012 https://doi.org/10.3892/or.2012.1888
Pages: 883-888

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Malignant pleural mesothelioma (MPM) is locally aggressive and challenging to quantitate non-invasively in vivo, particularly in orthotopic models of disease. We describe imaging of extracellular protease activity, typically elevated in locally aggressive tumors, as a novel method for tracking MPM in vivo. Mice bearing human MPM subcutaneous flank xenografted tumors were imaged with ProSense 680, an optical imaging agent of extracellular cysteine protease activity. The relative contribution of extracellular cysteine proteases to the ProSense tumor signal was estimated using RT-PCR quantitation of cysteine protease RNA expression of the MPM cell lines and compared to ArrayExpress microarray RNA expression data from human MPM tumors. Feasibility of orthotopic intraperitoneal MPM cell mass tracking with fluorescence signal was evaluated using CellVue Maroon-coated MSTO-211H and compared to bioluminescent signal using luciferase-transfected MSTO-211H cells. ProSense 680 yielded a robust tumor signal in MPM subcutaneous grafts, primarily resulting from MPM secretion of cathepsin L demonstrated not only by RT-PCR data on MPM cell lines but also by microarray expression data from resected human patient tumors. CellVue Maroon intraperitoneal tumor signal was robust and durable indicating feasibility of intraperitoneal cell mass tracking of orthotopically-xenografted MPM. Optical imaging of extracellular cysteine protease activity is useful for tracking MPM tumor cell mass in vivo. Intraperitoneal MPM cell mass tracking of fluorescently labeled tumor is feasible.

View Figures

View References

1	Bibby MC: Orthotopic models of cancer for preclinical drug evaluation: advantages and disadvantages. Eur J Cancer. 40:852–857. 2004. View Article : Google Scholar : PubMed/NCBI
2	Grisanzio C, Seeley A, Chang M, et al: Orthotopic xenografts of RCC retain histological, immunophenotypic and genetic features of tumours in patients. J Pathol. 225:212–221. 2011. View Article : Google Scholar : PubMed/NCBI
3	Chan E, Patel A, Heston W and Larchian W: Mouse orthotopic models for bladder cancer research. BJU Int. 104:1286–1291. 2009. View Article : Google Scholar : PubMed/NCBI
4	Hoffman RM: Orthotopic metastatic mouse models for anticancer drug discovery and evaluation: a bridge to the clinic. Invest New Drugs. 17:343–359. 1999. View Article : Google Scholar : PubMed/NCBI
5	Yang M, Jiang P, Sun FX, et al: A fluorescent orthotopic bone metastasis model of human prostate cancer. Cancer Res. 59:781–786. 1999.PubMed/NCBI
6	Gros SJ, Dohrmann T, Rawnaq T, et al: Orthotopic fluorescent peritoneal carcinomatosis model of esophageal cancer. Anticancer Res. 30:3933–3938. 2010.PubMed/NCBI
7	Nakataki E, Yano S, Matsumori Y, et al: Novel orthotopic implantation model of human malignant pleural mesothelioma (EHMES-10 cells) highly expressing vascular endothelial growth factor and its receptor. Cancer Sci. 97:183–191. 2006. View Article : Google Scholar
8	Moolgavkar SH, Meza R and Turim J: Pleural and peritoneal mesotheliomas in SEER: age effects and temporal trends, 1973–2005. Cancer Causes Control. 20:935–944. 2009.PubMed/NCBI
9	Yamaoka N, Kawasaki Y, Xu Y, et al: Establishment of in vivo fluorescence imaging in mouse models of malignant mesothelioma. Int J Oncol. 37:273–279. 2010.
10	Sloane BF: Cathepsin B and cystatins: evidence for a role in cancer progression. Semin Cancer Biol. 1:137–152. 1990.PubMed/NCBI
11	Wang W and El-Deiry WS: Bioluminescent molecular imaging of endogenous and exogenous p53-mediated transcription in vitro and in vivo using an HCT116 human colon carcinoma xenograft model. Cancer Biol Ther. 2:196–202. 2003. View Article : Google Scholar
12	Roe OD, Anderssen E, Helge E, et al: Genome-wide profile of pleural mesothelioma versus parietal and visceral pleura: the emerging gene portrait of the mesothelioma phenotype. PLoS One. 4:e65542004. View Article : Google Scholar : PubMed/NCBI
13	Klipper-Aurbach Y, Wasserman M, Braunspiegel-Weintrob N, et al: Mathematical formulae for the prediction of the residual beta cell function during the first two years of disease in children and adolescents with insulin-dependent diabetes mellitus. Med Hypotheses. 45:486–490. 1995.
14	Lankelma JM, Voorend DM, Barwari T, et al: Cathepsin L, target in cancer treatment? Life Sci. 86:225–233. 2010. View Article : Google Scholar : PubMed/NCBI
15	DeLong P, Carroll RG, Henry AC, et al: Regulatory T cells and cytokines in malignant pleural effusions secondary to mesothelioma and carcinoma. Cancer Biol Ther. 4:342–346. 2005. View Article : Google Scholar : PubMed/NCBI
16	Yamaguchi T, Naruishi K, Arai H, Nishimura F and Takashiba S: IL-6/sIL-6R enhances cathepsin B and L production via caveolin-1-mediated JNK-AP-1 pathway in human gingival fibroblasts. J Cell Physiol. 217:423–432. 2008. View Article : Google Scholar : PubMed/NCBI
17	Gerber A, Wille A, Welte T, Ansorge S and Buhling F: Interleukin-6 and transforming growth factor-β1 control expression of cathepsins B and L in human lung epithelial cells. J Interferon Cytokine Res. 21:11–19. 2001.
18	D'Angelo ME, Bird PI, Peters C, Reinheckel T, Trapani JA and Sutton VR: Cathepsin H is an additional convertase of pro-granzyme B. J Biol Chem. 285:20514–20519. 2010. View Article : Google Scholar : PubMed/NCBI
19	Asagiri M, Hirai T, Kunigami T, et al: Cathepsin K-dependent toll-like receptor 9 signaling revealed in experimental arthritis. Science. 319:624–627. 2008. View Article : Google Scholar : PubMed/NCBI
20	Nagai A, Murakawa Y, Terashima M, et al: Cystatin C and cathepsin B in CSF from patients with inflammatory neurologic diseases. Neurology. 55:1828–1832. 2000. View Article : Google Scholar : PubMed/NCBI
21	Martin SL, Moffitt KL, McDowell A, et al: Association of airway cathepsin B and S with inflammation in cystic fibrosis. Pediatr Pulmonol. 45:860–868. 2010. View Article : Google Scholar : PubMed/NCBI
22	Brutkiewicz S, Mendonca M, Stantz K, et al: The expression level of luciferase within tumour cells can alter tumour growth upon in vivo bioluminescence imaging. Luminescence. 22:221–228. 2007. View Article : Google Scholar : PubMed/NCBI